Even as weight-loss drugs such as Wegovy and Zepbound explode in popularity, many Americans struggle to afford them.

The biotech industry can be volatile even for relatively large companies. Amgen ( AMGN 1.00%), one of the more prominent names in the game, just reminded us all of that fact. On Nov. 26, the company's ...

Dr. Oz has extolled Ozempic’s promise for weight-loss. Now Medicare, which Trump wants Oz to oversee, may cover it.

This follows the immense popularity of injectible GLP1R drugs, such as Novo Nordisk (Wegovy and Saxenda), Eli Lilly (Zepbound), and Shanghai Benemae Pharmaceutical (Yishengtai), approved for obesity.

"Elon Musk is right," the senator tweeted. "The Pentagon, with a budget of $886 billion, just failed its 7th audit in a row.

Private insurance companies say U.S. patients aren't paying the true cost of expensive medications such as Wegovy and Zepbound, which can easily cost upwards of $1,000. Wegovy, the weight-loss ...

We recently published a list of 12 Best ADR Stocks To Invest In According to Analysts. In this article, we are going to take ...

Macy’s is investigating how hundreds of millions of dollars were hidden by one employee. The retailer delayed its quarterly ...

Whether millions gain access to breakthrough anti-obesity treatments may depend on Kennedy, Mehmet Oz and other key players ...

Few companies garner as much reliable attention as Novo Nordisk ( NVO) does these days. With a bull market coinciding with a ...

Novo Nordisk shifts its recruitment focus to China, expanding operations to meet rising demand for Ozempic and Wegovy in the ...